CollPlant Biotechnologies Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	2.37	0.52	10.96	0.3	15.64
Revenue Growth (YoY)	360.39%	-95.30%	3565.22%	-98.09%	154.86%
Cost of Revenue	0.84	1.63	1.99	0.4	2.01
Gross Profit	1.54	-1.11	8.97	-0.1	13.64
Selling, General & Admin	4.83	5.63	6	-	-
Research & Development	8.19	10.52	10.48	-	-
Total Operating Expenses	13.02	16.14	16.48	0	0
Operating Income	11.48	17.25	7.51	17.1	0.07
Total Non-Operating Income (Expense)	-0.01	0.64	0.49	0.17	0.17
Pretax Income	11.48	17.89	8.01	17.27	0.24
Net Income	11.49	16.61	7.02	16.93	0.24
Net Income to Common	11.49	16.61	7.02	16.93	0.24
Net Income Growth	-30.83%	136.63%	-58.53%	7041.35%	-
Shares Outstanding (Basic)	12	11	11	11	10
Shares Outstanding (Diluted)	12	11	11	11	12
Shares Change (YoY)	6.54%	0.57%	3.23%	-7.80%	73.76%
EPS (Basic)	-0.94	-1.45	-0.62	-1.53	0.02
EPS (Diluted)	-0.94	-1.45	-0.62	-1.53	0.02
Shares Outstanding	12.8	11.45	11.45	11.19	10.72
Free Cash Flow	-9.45	-14.58	-3.72	-14.97	1.07
Free Cash Flow Per Share	-0.77	-1.27	-0.33	-1.36	0.09
Gross Margin	64.78%	-215.53%	81.83%	-33.78%	87.18%
Operating Margin	484.31%	3349.71%	68.55%	5718.06%	0.42%
Profit Margin	484.06%	3474.37%	73.05%	5775.59%	1.52%
FCF Margin	-398.44%	-2830.29%	-33.92%	-5007.36%	6.86%
EBITDA	12.4	18.29	8.61	18.17	0.84
EBITDA Margin	522.78%	3551.26%	78.60%	6077.93%	5.36%
EBIT	11.48	17.25	7.51	17.1	0.07
EBIT Margin	484.31%	3349.71%	68.55%	5718.06%	0.42%

Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q